8-K: Omeros Corporation Announces Fourth Quarter and Year-End 2024 Financial Results; Narsoplimab BLA Resubmitted to FDA

Omeros Corporation reports its Q4 and year-end 2024 financial results, highlighted by the resubmission of the narsoplimab BLA to the FDA and progress in its clinical development programs.

Summary

• Omeros Corporation announced its financial results for the fourth quarter and year ended December 31, 2024.
• The company reported a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024, compared to a net loss of $32.2 million, or $0.56 per share, for the third quarter of 2024.
• For the year ended December 31, 2024, the net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117.8 million, or $1.88 per share in the prior year.
• At December 31, 2024, Omeros had $90.1 million in cash and short-term investments available for operations and debt servicing, a decrease of $81.7 million from December 31, 2023.
• The company resubmitted its Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) to the FDA.
• The expected target date for FDA action under the Prescription Drug User Fee Act (PDUFA) is in September 2025.
• Omeros expects to submit its European marketing authorization application (MAA) for narsoplimab in TA-TMA in the first half of 2025.
• Site activation has begun for the Phase 3 development program evaluating zaltenibart for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a significant net loss and a decrease in cash, there are positive developments such as the resubmission of the narsoplimab BLA, the initiation of the Phase 3 program for zaltenibart, and the NIDA funding commitment. The management's comments are also optimistic.

Positives

• The BLA for narsoplimab was resubmitted to the FDA, with a PDUFA date expected in September 2025.
• The MAA for narsoplimab is expected to be submitted to the EMA in the first half of 2025.
• Phase 3 clinical program for zaltenibart in PNH has been initiated.
• NIDA confirmed its funding commitment of $4.02 million for the OMS527 trial in patients with cocaine use disorder.
• OMS721-TMA-001 patients demonstrated clinically meaningful and statistically significant superiority in overall survival with a hazard ratio of 0.32 (95% confidence interval: 0.23 to 0.44) with p-value less than 0.00001 compared to the TA-TMA patients in the external registry.

Negatives

• The company reported a net loss of $156.8 million for the year ended December 31, 2024.
• Cash and short-term investments decreased by $81.7 million from December 31, 2023, to $90.1 million as of December 31, 2024.

Risks

• The company's actual results could differ materially from those anticipated in forward-looking statements due to various factors, including regulatory processes, clinical development activities, financial condition, and competitive developments.
• There are risks associated with the manufacture or supply of products to support clinical trials and potential commercial sales.
• Changes in reimbursement and payment policies by government and commercial payers could impact the company's financial performance.
• Intellectual property claims and litigation pose risks to the company's operations.

Future Outlook

Omeros anticipates a PDUFA date in September 2025 for narsoplimab and expects to submit its MAA to the EMA in the first half of 2025. The company is also focused on advancing its clinical programs and establishing ex-U.S. partnerships.

Management Comments

• Gregory A. Demopulos, M.D., Chairman and CEO of Omeros, stated that all study results in the BLA are uniformly strong across all comparative analyses and all datasets.
• Dr. Demopulos mentioned that the company looks forward to working closely with the FDA toward narsoplimab's approval and that the commercial team is well-prepared to execute a successful market launch.
• Dr. Demopulos noted that zaltenibart's compelling results in Phase 2 PNH trials are highly predictive of the ongoing Phase 3 program, which remains on track to readout data late next year.

Industry Context

Omeros is focused on developing therapeutics for immunologic disorders, including complement-mediated diseases. The resubmission of the narsoplimab BLA and the progress of zaltenibart in PNH position the company to potentially address unmet needs in these areas. The company is also advancing its oncology platform and exploring treatments for addictive and compulsive disorders.

Comparison to Industry Standards

• The hazard ratio of 0.32 for overall survival in TA-TMA patients treated with narsoplimab compared to an external control registry suggests a significant improvement over standard care.
• The reported survival in eculizumab-refractory patients treated with narsoplimab showed an over three-fold increase in one-year survival compared to the reported survival in eculizumab-refractory patients of 20 percent or less.
• These results position narsoplimab as a potential best-in-class treatment for TA-TMA, especially in patients who have failed other therapies like eculizumab, which is marketed by Alexion Pharmaceuticals (now part of AstraZeneca).

Stakeholder Impact

• Shareholders may be impacted by the financial results and the progress of the company's clinical programs.
• Employees are affected by the company's financial stability and the advancement of its pipeline.
• Patients with TA-TMA and PNH may benefit from the potential approval and commercialization of narsoplimab and zaltenibart, respectively.
• The NIDA funding for the OMS527 program could lead to new treatments for cocaine use disorder.

Next Steps

• FDA review of the resubmitted BLA for narsoplimab, with a PDUFA date expected in September 2025.
• Submission of the MAA for narsoplimab to the EMA in the first half of 2025.
• Continuation of the Phase 3 clinical program for zaltenibart in PNH.
• Advancement of the OMS527 trial in patients with cocaine use disorder.
• Sharing further information on the oncology platform programs in the near term.

Key Dates

Keywords

narsoplimab, zaltenibart, OMS527, TA-TMA, PNH, Cocaine Use Disorder, BLA, MAA, FDA, EMA, MASP-2, MASP-3, Omeros, Financial Results, Clinical Trials